Magseed and Magtrace Localization for Breast Cancer

CompletedOBSERVATIONAL
Enrollment

70

Participants

Timeline

Start Date

May 4, 2020

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2023

Conditions
Breast CarcinomaBreast Carcinoma Metastatic in Lymph Node
Interventions
PROCEDURE

Magseed

Patients with the non-palpable histologically confirmed breast cancer lesion - the tumor lesion will be labeled with Magseed and patient will undergo breast-conserving surgery and sentinel lymph node detection with Tc99.

PROCEDURE

Magtrace

Patients with the palpable histologically confirmed breast cancer lesion - The Magtrace will be injected preoperatively into the tumor and detected by Sentimag. Patient will undergo sentinel lymph node detection with Tc99 and Sentimag localization system with breast surgery.

PROCEDURE

Axillary lymph node metastasis - needle biopsy

Patients with the histologically confirmed breast cancer lesion with Axillary lymph node metastasis with pathologic confirmation by needle biopsy - the positive axillary lymph node lesion will be labeled with Magseed before the neoadjuvant systemic therapy, and later during target axillary dissection will be performed the biopsy of labeled lymph node during breast surgery.

Trial Locations (1)

70852

University Hospital Ostrava, Ostrava

All Listed Sponsors
lead

University Hospital Ostrava

OTHER

NCT05161507 - Magseed and Magtrace Localization for Breast Cancer | Biotech Hunter | Biotech Hunter